Skip to main content
TipRanks
Go Ultimate75% OFF

Imagion Biosystems Ltd. (IBX) AI Stock Analysis

18 Followers
AU:IBX

Imagion Biosystems Ltd.

(ASX:IBX)

Select Model
Rating:37Underperform
Price Target:AUD 0.01â–²(80.00% Upside)
Action:reiterated
Date:09/26/26

AU:IBX receives the minimum score due to an extremely precarious financial position, characterized by zero revenue, technical insolvency, and severe unprofitability. A complete lack of technical momentum and a highly negative valuation profile further emphasize immediate solvency risks, rendering the company heavily reliant on external capital to survive.

Positive Factors
Differentiated imaging platformThe MagSense® platform combines targeted nanoparticles with MPI, giving the company a defined technology approach rather than a broad, undifferentiated diagnostic offering. If development succeeds, this platform could support a focused and repeatable product strategy in molecular cancer imaging.
Negative Factors
Revenue deteriorationRevenue reaching zero in 2025 demonstrates that the business has not yet established dependable commercial traction. The reversal from earlier modest growth weakens visibility into customer adoption and makes it difficult for the company to fund research, commercialization, and operations through recurring sales.

Imagion Biosystems Ltd. (IBX) vs. iShares MSCI Australia ETF (EWA)

-50%-25%0%25%50%75%AU:IBX-47.37%EWA+8.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 2.97M
Dividend Yield
―
Average Volume (3M)
893.08K
Price to Earnings (P/E)
-0.5
Beta (1Y)
1.74
Revenue Growth
-100.00%
EPS Growth
-3.67%
Country
Australia
Employees
11
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

Imagion Biosystems Ltd. Business Overview & Revenue Model

Company Description

Imagion Biosystems Limited operates as a medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases in Australia. The company is involved in nanotechnology; biotechnology; medical imaging using magnetic reso...

Imagion Biosystems Ltd. Financial Statement Overview

Summary

Financial performance reflects severe distress with zero recent revenue, negative stockholders' equity, and persistent cash burn, raising immediate solvency risks.

Income Statement

8Very Negative

Balance Sheet

5Very Negative

Cash Flow

12Very Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue002.67M1.08M473.43K232.87K
Gross Profit-6,369-8,8082.26M-279.83K-3.14M-2.47M
EBITDA-4.67M-3.58M-355.52K-10.30M-11.03M-5.62M
Net Income-4.63M-4.31M-2.07M-12.47M-9.81M-6.02M
Balance Sheet
Total Assets671.92K2.04M2.80M4.59M9.98M14.12M
Cash, Cash Equivalents and Short-Term Investments32.46K1.85M2.67M227.08K4.45M13.39M
Total Debt2.19M2.56M2.85M6.04M4.60M46.02K
Total Liabilities4.09M4.21M5.09M8.37M5.30M809.88K
Stockholders Equity-3.42M-2.16M-2.28M-3.79M4.68M13.31M
Cash Flow
Free Cash Flow-4.05M-4.04M-1.27M-8.51M-9.21M-5.29M
Operating Cash Flow-4.05M-4.04M-1.27M-8.32M-8.70M-5.07M
Investing Cash Flow0083.74K-190.38K-468.73K-310.09K
Financing Cash Flow3.23M3.24M3.61M4.29M-962.06K5.15M

Imagion Biosystems Ltd. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:IBX against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:IDXAU:IDX48NeutralAUD 619.98M28.323.24%5.60%25.73%390.83%
AU:BDXAU:BDX42NeutralAUD 22.20M-2.98-881.94%―743.51%-1.52%
AU:GSSAU:GSS38UnderperformAUD 16.35M-1.14-35.10%―-9.10%31.75%
AU:RHYAU:RHY38UnderperformAUD 21.84M-3.39-205.17%―239.64%-37.21%
AU:IBXAU:IBX37UnderperformAUD 4.02M-0.49165.88%―-100.00%-3.67%

* Healthcare Sector Average

Performance Comparison

0%100%AU:IBXAU:BDXAU:RHYAU:GSSAU:IDXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:IBX and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:IBXImagion Biosystems Ltd.0.01-0.01-52.38%
AU:BDXBCAL Diagnostics Limited0.06-0.03-33.33%
AU:RHYRhythm Biosciences Ltd.0.06-0.04-36.84%
AU:GSSGenetic Signatures Ltd.0.07-0.21-74.55%
AU:IDXIntegral Diagnostics Ltd.1.69-0.77-31.50%

Imagion Biosystems Ltd. Corporate Events

Imagion Executes First U.S. Site Agreement for MagSense HER2+ Breast Cancer Trial

Nov 16, 2026

Imagion Biosystems has executed a Clinical Trial Agreement with oncology-focused Regis Clinical Research, its first contracted site for the MagSense HER2 Imaging Agent Phase 1b/2 trial in HER2+ breast cancer. The agreement enables progress toward sit...

Imagion Biosystems Issues Shares for Corporate Advisory Services

Nov 6, 2026

Imagion Biosystems is a clinical-stage medical imaging company developing MagSense®, a non-radioactive magnetic nanoparticle MRI agent designed to support earlier and more precise cancer detection. Its applications target HER2-positive breast, prosta...

Imagion Biosystems Issues Shares for Advisory Fees

Nov 6, 2026

Imagion Biosystems Limited reported the issue of 2,393,144 fully paid ordinary shares on November 6, 2026, in lieu of fees for corporate advisory services.The newly issued shares were applied for quotation on the Australian Securities Exchange under...

Imagion Biosystems Reshapes Board Roles as It Advances Cancer Imaging Programs

Oct 30, 2026

Imagion Biosystems has announced the resignation of Non-Executive Director and Company Secretary Melanie Leydin, effective 30 October 2026, coinciding with her retirement and a shift in focus to other commitments. Leydin, who joined the board in Augu...

Imagion Biosystems Corrects Convertible Note Balance in Amended Quarterly Cash Report

Oct 26, 2026

Imagion Biosystems has lodged an amended Appendix 4C for the quarter ended 30 September 2026 to correct the reported balance of its financing facilities. The revision updates the value of outstanding convertible notes under a $15 million facility wit...

Imagion Biosystems Advances U.S. MagSense HER2 Trial and Restores Nanoparticle Manufacturing

Oct 7, 2026

Imagion Biosystems reported substantial progress in preparing its Phase 1b/2 MagSense® HER2 breast cancer clinical trial in the U.S., moving towards first patient enrolment. The company has finalized key study materials, completed manufacturing and s...

Imagion Wins Central Ethics Approval for Phase 2 MagSense Cancer Trial

Sep 30, 2026

Imagion Biosystems has secured central Institutional Review Board ethics approval from Advarra for its Phase 1b/2 trial of the MagSense® HER2 imaging agent in HER2-positive breast cancer. This clearance, combined with prior FDA IND approval, meets ke...

Imagion Biosystems Restores MagSense Nanoparticle Manufacturing via nanoComposix Deal

Sep 13, 2026

Imagion Biosystems has signed a Master Service Agreement with nanoComposix, a specialty nanoparticle CDMO, to resume pharmaceutical-grade manufacturing of its MagSense® nanoparticles in alignment with U.S. FDA product quality standards. By outsourcin...

Imagion Biosystems promotes molecular MRI platform for early cancer detection

Sep 3, 2026

Imagion Biosystems has released an investor presentation outlining its molecular MRI platform as a next-generation imaging technology for early cancer detection. The company positions this approach as a breakthrough in oncology imaging, aiming to enh...

Imagion Biosystems issues cleansing notice on new options

Sep 1, 2026

Imagion Biosystems has issued a cleansing notice following the allotment of 40,208,334 listed options expiring on 13 December 2027, including options granted to participants in a recent placement and to the lead manager. The options were issued witho...

Imagion Biosystems Seeks ASX Quotation for 7.5 Million New Options

Sep 1, 2026

Imagion Biosystems Limited has applied to the ASX for quotation of new options, designated under the security code IBXO, further integrating these instruments into its listed securities structure. The options relate to securities issued to the lead m...

Imagion Biosystems Seeks ASX Quotation for 32.7 Million Options

Sep 1, 2026

Imagion Biosystems has applied to the ASX for quotation of new options under the code IBXO, expanding its listed securities on the market. The company is seeking quotation for a total of 32,708,334 options expiring on 13 December 2027, issued across...

Imagion Biosystems Options Lapse, Streamlining Capital Structure

Aug 27, 2026

Imagion Biosystems has announced the expiry and cessation of 1,164,597 listed options with the ASX code IBXAAU, which carried an exercise price of $0.90 and an expiry date of August 25, 2026. The options lapsed without being exercised, resulting in a...

Imagion Biosystems Details Director’s Milestone-Linked Equity Holdings

Aug 25, 2026

Imagion Biosystems has disclosed a change in Director Robert Romeo Proulx’s interests in the company’s securities, detailing his holdings of ordinary shares, listed and unlisted options, and multiple classes of performance rights tied to clinical and...

Imagion Biosystems Half-Year Loss Widens as Auditors Flag Going-Concern Risk

Aug 24, 2026

Imagion Biosystems reported a half-year loss after tax of $1.98 million for the period ended 30 June 2026, a 19.2% increase on the prior corresponding period, with no dividends declared or paid. Net tangible assets per share fell to negative 0.63 cen...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 26, 2026